SEMAX peptide therapy

SEMAX is a research peptide derived from a short fragment of adrenocorticotropic hormone (ACTH 4-10). It’s explored for its nootropic and neuroprotective potential—supporting attention, memory, and brain resilience. At The Catalyst Clinic, SEMAX is considered only within a physician-led programme with appropriate screening and follow-up.

What is SEMAX?

SEMAX is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) engineered to retain the neurotrophic properties of ACTH fragments without hormonal activity. It’s typically delivered intranasally (and in some research settings by injection) due to poor oral bioavailability. Developed in Russia, it has been used there in clinical contexts, though high-quality, English-language human data remain limited. Alzheimer's Drug Discovery Foundation+1

  • Neurotrophic signalling: Preclinical research shows SEMAX can increase brain-derived neurotrophic factor (BDNF) in specific brain regions, a molecule linked to synaptic plasticity and learning. PubMed

  • Neurochemical modulation: Studies indicate effects on serotonergic and dopaminergic systems, which may relate to attention and mood. PubMed

In plain terms: SEMAX may help the brain adapt and perform by influencing growth factors and neurotransmitter systems. Evidence in healthy adults and patients is still developing.

Benefits of SEMAX

  • • Fat reduction – improved fat metabolism and body composition
  • • Offer neuroprotective support in settings like stroke recovery (evidence base limited and mostly outside the UK/US).
  • • Modulate brain networks involved in anxiety/emotional regulation and executive function (human fMRI).

How SEMAX Works

  • • Upregulating BDNF and other neurotrophins, supporting synaptic plasticity.
  • • Influencing monoamine pathways (serotonin/dopamine) associated with attention, focus, and mood.
  • • Possible enzyme inhibition affecting endogenous peptide signalling (clinical significance uncertain).

Potential Therapeutic Applications

  • • Cognitive support (focus, memory, mental stamina) in healthy or high-demand individuals.
  • • Adjunctive neurorehabilitation (e.g., stroke recovery) in regions where SEMAX is used clinically.
  • • Stress and mood regulation in conjunction with lifestyle and clinical care plans.
  • • Metabolic health and fat loss

Note: SEMAX is not FDA-approved and is considered investigational in the UK/US; use is limited to carefully supervised contexts.

Safety, Side Effects & Administration

SEMAX is generally well tolerated, but possible side effects include:

  • • Intranasal irritation or discoloration, occasional headache; long-term effects are unknown.
  • • Regulatory agencies note immunogenicity risks for compounded peptides and limited safety information for proposed routes of administration.

Long-term effects are still under study. At The Catalyst Clinic, peptide therapy is only offered after full consultation and ongoing medical monitoring.

Administration: Typically delivered via subcutaneous injection. Cyclcing of this is essential.

Treatment Process at The Catalyst Clinic

1

Consultation

Full assessment of your goals, health status, and suitability.

2

Tailored Plan

If appropriate, SEMAX may be included in your personalised peptide programme.

3

Ongoing Support

Regular monitoring to ensure effectiveness and safety.

Our clinics in London, New York, and Zurich provide international access to advanced peptide therapy.

 FAQs

  • Primarily investigated for attention, memory, and neuroprotection, with clinical use historically reported in Russia; robust Western trials are still sparse.

  • Most commonly intranasally in research or clinical settings where permitted; dosing and duration are individualized under medical supervision.

  • Short-term tolerability appears acceptable in limited reports, but comprehensive human safety data are lacking; long-term effects are unknown.

  • SEMAX is not FDA-approved and is treated as investigational in many jurisdictions; US regulators highlight risks with compounded peptide products. Check local regulations and always use under medical supervision.

  • They act on different neurobiological pathways and are sometimes discussed together, but combination use should only be considered clinically after individual assessment.

Book a Consultation

Interested in SEMAX peptide therapy?
Contact The Catalyst Clinic in London, New York, or Zürich today to book your consultation.